Spotlight on mycophenolate mofetil in MS

Drug News and Perspectives

Volumn 19, Issue 10, 2006, Pages 632-633

  Davies, S L ^a   Moral, M A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHAN1 INTERFERON; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; BETA INTERFERON; DRUG DERIVATIVE; ENZYME INHIBITOR; IMMUNOLOGIC FACTOR; IMMUNOLOGICAL ADJUVANT; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID;

CARDIAC GRAFT REJECTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CROHN DISEASE; DISEASE COURSE; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FOOD AND DRUG ADMINISTRATION; HUMAN; KIDNEY GRAFT REJECTION; LIVER GRAFT REJECTION; MONOTHERAPY; MULTIPLE SCLEROSIS; SHORT SURVEY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; DRUG ANTAGONISM; DRUG COMBINATION; ENZYMOLOGY; METABOLISM; REVIEW; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS; IMP DEHYDROGENASE; INTERFERON-BETA; MULTIPLE SCLEROSIS; MYCOPHENOLIC ACID; TREATMENT OUTCOME;

EID: 34247553896     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (15)

1. Taylor, R.S. Immunologic aspects of multiple sclerosis. Phys Med Rehabil Clin North Am 1998, 9: 525-36, v.
2. Frohman, E.M., Filippi, M., Stuve, O. et al. Characterizing the mechanisms of progres sion in multiple sclerosis: evidence and new hypotheses for future directions. Arch Neurol 2005, 62: 1345-56.
3. Popko, B. and Baerwald, K.D. Oligodendroglial response to the immune cytokine interferon gamma. Neurochem Res 1999, 24: 331-8.
4. Yong, V.W., Chabot, S., Stuve, O. and Williams, G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998, 51: 682-9.
5. Mamelok, R. From mechanisms to long-term benefits. Transplantation 2005, 79: S43-S44.
6. Miljkovic, D.J., Samardzic, T., Drakulic, D., Stosic-Grujicic, S. and Trajkovic, V. Immunosuppressants leflunomide and mycophenolic acid inhibit fibroblast IL-6 production by distinct mechanisms. Cytokine 2002, 19: 181-6.
7. Neurath, M.F., Wanitschke, R., Peters, M., Krummenauer, F., Meyer zum Buschenfelde, K.H. and Schlaak, J.F. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut 1999, 44: 625-8.
8. Ahrens, N., Salama, A. and Haas, J. Mycophenolate-mofetil in the treatment of refractory multiple sclerosis. J Neurol 2001, 248: 713-4.
9. Vukusic, S., Ducray, F., Gignoux, L. et al. Mycophenolate mofetil: An open-label study in 42 MS patients. Neurology 2004, 62(7, Suppl. 5): Abst P06.088.
10. Frohman, E.M., Brannon, K., Racke, M.K. and Hawker, K. Mycophenolate mofetil in multiple sclerosis. Clin Neuropharmacol 2004, 27: 80-3.
11. Vermersch, P., Waucquier, N., Bourteel, H. et al. Treatment of multiple sclerosis with a combination of interferon beta-1a (Avonex) and mycophenolate mofetil (Cellcept): Results of a phase II clinical trial. Neurology 2004, 62(7, Suppl. 5): Abst S29.001.
12. Gogovska, L. and Ljapcev. R. Mycophenolate mofetil plus interferon beta in multiple sclerosis. J Neurol Sci [18th World Congr Neurol (November 5-11, Sydney, Australia) 2005] 2005, 238(Suppl. 1): Abst 0505.
13. Milder, D. Immunomodulatory therapies and mycophenolate-mofetil or low-dose azathioprine reverse partially and significantly visual and neurologic deficits in progressive forms of multiple sclerosis. Multiple Scler 2004, 10(Suppl. 2): Abst P660.
14. Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis (NCT00324506). ClinicalTrials. gov Web Site 2006, June 8.
15. Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis (NCT00223301). ClinicalTrials.gov Web Site 2006, April 12.